Lipocine launches Phase 3 BLOOM study for PPD
Lipocine said it initiated the BLOOM Phase 3 study of LPCN 1154 for postpartum depression and expects first dosing in early Q4 2026. The company also said it plans about 120 patients and expects monthly cash use of about $1 million.